EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company's Board as an independent Non-Executive Director.

Mr Stamp has extensive experience of the specialty pharmaceutical sector having previously held Board-level roles at Xanodyne Pharmaceuticals Inc. and Shire Pharmaceuticals Plc, and most recently as Chief Financial Officer of K-V Pharmaceutical Company. Mr Stamp has considerable financial expertise developed during a career spanning over 25 years, including more than 10 years in corporate finance and investment banking. He is an Associate Member of the Institute of Chartered Accountants.

"I want to warmly welcome Stephen to EUSA Pharma," said Rolf Stahel, EUSA Pharma's Chairman. "Since its foundation four years ago, EUSA has established itself as a successful transatlantic specialty pharma business, and is now entering its next phase of rapid and profitable growth. Stephen's financial expertise, and history of success in our industry, will prove an important asset as we transition EUSA into one of the most successful companies in its field."

Commenting on his appointment, Stephen A. Stamp said, "Having witnessed EUSA's impressive growth, I am excited to be helping the company achieve its ambitious plans. Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company's continued rapid development."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and spread of prostate cancer and Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 80 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

    Contacts

    Bryan Morton
    Chief Executive EUSA Pharma
    Tel: +44(0)1865-784255

    Rob Budge
    RJB Communications
    Tel: +44(0)1865-760969
    Mobile: +44(0)7710-741241

SOURCE EUSA Pharma